Holen Sie sich die Stockscreener-App
12.61
6.86%
0.81
Handel nachbörslich:
12.44
-0.17
-1.35%
Schlusskurs vom Vortag:
$11.80
Offen:
$12
24-Stunden-Volumen:
249.92K
Relative Volume:
1.11
Marktkapitalisierung:
$493.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+8.43%
1M Leistung:
+7.14%
6M Leistung:
-36.86%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.81
$12.79
1-Wochen-Bereich:
$10.83
$12.79
52-Wochen-Spanne:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Firmenname
Oruka Therapeutics Inc
Sektor
Branche
Telefon
650-606-7910
Adresse
855 OAK GROVE AVE., MENLO PARK
Vergleichen Sie ORKA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
12.61 | 493.84M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-11 | Eingeleitet | Stifel | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-16 | Eingeleitet | TD Cowen | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-02-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Eingeleitet | Dawson James | Buy |
Alle ansehen
Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten
Wall Street Zen Downgrades Oruka Therapeutics (NASDAQ:ORKA) to Sell - Defense World
Millennium Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Squarepoint Ops LLC Acquires New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial - MSN
Oruka Therapeutics Holds Annual Stockholders Meeting - TipRanks
Jane Street Group LLC Buys New Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
HC Wainwright Has Positive Estimate for ORKA Q2 Earnings - Defense World
Northern Trust Corp Acquires Shares of 64,044 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
H.C. Wainwright maintains Buy on Oruka stock, $45 target By Investing.com - Investing.com India
H.C. Wainwright maintains Buy on Oruka stock, $45 target - Investing.com UK
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at BTIG Research - Defense World
BTIG Initiates Oruka Therapeutics at Buy With $44 Price Target - marketscreener.com
BTIG sets $44 price target on Oruka Therapeutics stock - Investing.com UK
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Oruka Therapeutics begins trial for psoriasis treatment By Investing.com - Investing.com South Africa
Oruka Therapeutics begins trial for psoriasis treatment - Investing.com Australia
Oruka Therapeutics Begins Dosing in Phase 1 Trial of ORKA-002 for Skin Disease Treatment - marketscreener.com
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody - GlobeNewswire
Revolutionary Psoriasis Treatment Begins Human Trials: Only 2-3 Doses Per Year Needed - Stock Titan
Wedbush Forecasts Reduced Earnings for Oruka Therapeutics - Defense World
What is Wedbush’s Estimate for ORKA FY2029 Earnings? - Defense World
Wedbush Reaffirms “Outperform” Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) versus Trinity Biotech (NASDAQ:TRIB) Critical Analysis - Defense World
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Oruka Therapeutics Announces Accelerated Clinical Timelines and Strong Financial Position for Psoriasis Programs - Nasdaq
Oruka Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
Oruka Therapeutics, Inc. SEC 10-Q Report - TradingView
Oruka Therapeutics (NASDAQ:ORKA) and Trinity Biotech (NASDAQ:TRIB) Head-To-Head Analysis - Defense World
JPMorgan Chase & Co. Acquires New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Barclays PLC Purchases Shares of 74,583 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
HC Wainwright Issues Negative Estimate for ORKA Earnings - Defense World
Equities Analysts Offer Predictions for ORKA Q1 Earnings - Defense World
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference - GlobeNewswire
Geode Capital Management LLC Boosts Stock Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Comparing TNF Pharmaceuticals (NASDAQ:TNFA) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Oruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on Thursday - Defense World
Vanguard Group Inc. Purchases 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - The AM Reporter
Vanguard Group Inc. Acquires 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Acquired by Wellington Management Group LLP - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Charles Schwab Investment Management Inc. Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Contrasting Achieve Life Sciences (NASDAQ:ACHV) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)
Es liegen keine Finanzdaten für Oruka Therapeutics Inc (ORKA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Oruka Therapeutics Inc-Aktie (ORKA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
11.63 |
14,950 |
173,868 |
4,059,634 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
11.86 |
8,971 |
106,396 |
4,044,684 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
10.95 |
9,593 |
105,043 |
4,035,713 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
10.90 |
574 |
6,257 |
4,026,120 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Aug 16 '24 |
Buy |
2.93 |
5,818 |
17,067 |
2,117,213 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 24 '24 |
Buy |
3.20 |
189,856 |
606,873 |
2,081,168 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 25 '24 |
Buy |
3.05 |
30,227 |
92,292 |
2,111,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 03 '24 |
Buy |
3.55 |
166,042 |
589,565 |
1,648,577 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 11 '24 |
Buy |
3.45 |
94,537 |
326,304 |
1,891,312 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 10 '24 |
Buy |
3.46 |
55,463 |
192,130 |
1,796,775 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):